IGF2BP1 and ovarian carcinoma: Using a fluorescence anisotropy-based assay, Mahapatra et al. screened 160,000 small molecules and identified a potent and selective IGF2BP1 inhibitor, BTYNB, which inhibited melanoma and ovarian cancer cell proliferation by downregulating several IGF2BP1-mediated mRNA transcripts, including c-Myc, β-TrCP1, NF-κB and eEF2 (Fig. 7a) [445].